NCT05121740 - Extension Study in a Cohort of Adult Patients With COVID-19 Infection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 25, 2022

Primary Completion Date

March 16, 2022

Study Completion Date

March 16, 2022

Conditions

COVID-19 Infection

Interventions

DRUG

Plitidepsin 1.5 mg / day

Plitidepsin 1.5 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 4.5 mg).

DRUG

Plitidepsin 2.0 mg / day

Plitidepsin 2.0 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 6.0 mg).

DRUG

Plitidepsin 2.5 mg / day

Plitidepsin 2.5 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 7.5 mg).

Trial Locations (10)

Hospital General de Ciudad Real, Ciudad Real

Hospital Universitario de Guadalajara, Guadalajara

Hospital General Universitario Gregorio Marañón, Madrid

Hospital Universitario Clínico San Carlos, Madrid

Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcón

Hospital Universitario HM Montepríncipe, Boadilla del Monte

Hospital Universitario Ramón y Cajal, Madrid

Hospital Universitario La Princesa, Madrid

Hospital Universitario de Getafe, Getafe

Hospital Universitari Germans Trias i Pujol, Badalona